Wang Linlin, Dong Yanguang, Li Qing, Li Hongjing, Sun Xiyin, Zhou Xiaoqiu, Li Xingong
Department of Pathology, the People's Hospital of Dongying, Dongying 257091, China.
E-mail:
Zhonghua Bing Li Xue Za Zhi. 2015 Feb;44(2):118-22.
To assess clinical and pathological features of ovarian transitional cell tumors.
Fourteen cases of ovarian transitional cell carcinoma (TCC) were selected and investigated for their clinical and pathological features. Their immunohistochemical profiles were compared with 12 cases of serous adenocarcinoma (SC) admixed with TCC and 4 cases of EC admixed with TCC 20 cases of pure high-grade serous adenocarcinoma (HG-SC), 15 cases of endometrioid adenocarcinoma (EC), 6 cases of Brenner tumor (BT, 2 cases of malignant BT and 4 cases of benign BT).
The patients' age ranged from 36-63 years (mean, 56 years). All cases underwent surgery and postoperative chemotherapy with TP or CAP program. Clinical follow-up was available in 9 cases, of which 2 patients died. Histologically, all cases showed features of transitional cell carcinoma without BT component. Immunohistochemically, 13 of 14 TCCs were positive for WT-1 and all were positive for CK7, ER, PR and CA125, but negative for Uroplakin III and CK20.Similar immunohistochemical staining patterns were seen in SC admixed with TCC and pure HG-SC. Percentage of the 14 TCC cases were also diffusely positive for BRCA1. All SCs admixed with TCC and pure HG-SCs were diffusely or heterogeneously positive for WT-1, with a sharp contrast and mottled distribution pattern in the heterogeneous cases. All TCCs were diffusely and strongly positive for p53, while 16 of 20 cases of pure HG-SC were positive. The positive ratio of p53 in SCs admixed with TCC cases was 11/12.WT-1 expression in TCCs was significantly higher than BTs, ECs and ECs admixed with TCC (P < 0.01), while no obvious difference was seen when compared with SCs admixed with TCC and pure HG-SCs.SCs admixed with TCC, TCCs and EC were positive for BRCA1 except pure ECs and BTs. The positive rate of Ki-67 of BTs was low, while it was higher in TCCs, SCs admixed with TCC and pure HG-SCs. Only BTs expressed Uroplakin III.
Ovarian TCC has characteristic morphological and immunohistochemical features, similar to SC but different from BT. Therefore, TCC should be considered as a morphological variant of HG-SC.
评估卵巢移行细胞肿瘤的临床和病理特征。
选取14例卵巢移行细胞癌（TCC）病例，对其临床和病理特征进行研究。将其免疫组化特征与12例合并TCC的浆液性腺癌（SC）、4例合并TCC的子宫内膜样癌（EC）、20例纯高级别浆液性腺癌（HG-SC）、15例子宫内膜样腺癌（EC）、6例勃勒纳瘤（BT，2例恶性BT和4例良性BT）进行比较。
患者年龄为36 - 63岁（平均56岁）。所有病例均接受手术及术后TP或CAP方案化疗。9例有临床随访资料，其中2例患者死亡。组织学上，所有病例均显示移行细胞癌特征，无BT成分。免疫组化方面，14例TCC中13例WT-1阳性，所有病例CK7、ER、PR和CA125均阳性，但尿路上皮蛋白III和CK20阴性。合并TCC的SC和纯HG-SC有相似的免疫组化染色模式。14例TCC病例中BRCA1也呈弥漫性阳性。所有合并TCC的SC和纯HG-SC中WT-1呈弥漫性或异质性阳性，异质性病例呈现鲜明对比和斑驳分布模式。所有TCC中p53呈弥漫性强阳性，而20例纯HG-SC中有16例阳性。合并TCC的SC病例中p53阳性率为11/12。TCC中WT-1表达显著高于BT、EC及合并TCC的EC（P < 0.01），而与合并TCC的SC和纯HG-SC相比无明显差异。除纯EC和BT外，合并TCC的SC、TCC和EC中BRCA1阳性。BT的Ki-67阳性率低，而TCC、合并TCC的SC和纯HG-SC中较高。只有BT表达尿路上皮蛋白III。
卵巢TCC具有特征性的形态学和免疫组化特征，与SC相似但与BT不同。因此，TCC应被视为HG-SC的一种形态学变异型。
